FARRAGUT PARTNERS LLP for GENENTECH
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Concerns regarding Meicare payment policies for Part B drugs. Issues related to the 340B Drug discount program. Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148- "Patient Protection and Affordable Care Act". Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEFF MACKINNON New | LD and LA Rep. Joe Barton (R-Texas) |
| JEFFERY C. MORTIER New | Prof Staff on E&C Cmte and LA Rep Whitfield |
| JOSEPH V VASAPOLI New | Min.Counsel, Energy&Comm, Special Asst. DOE |
Health Issues HCR
Concerns regarding Meicare payment policies for Part B drugs. Issues related to the 340B Drug discount program. Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148- "Patient Protection and Affordable Care Act". Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEFF MACKINNON New | LD and LA Rep. Joe Barton (R-Texas) |
| JEFFERY C. MORTIER New | Prof Staff on E&C Cmte and LA Rep Whitfield |
| JOSEPH V VASAPOLI New | Min.Counsel, Energy&Comm, Special Asst. DOE |
Pharmacy PHA
Concerns regarding Meicare payment policies for Part B drugs. Issues related to the 340B Drug discount program. Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148- "Patient Protection and Affordable Care Act". Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEFF MACKINNON New | LD and LA Rep. Joe Barton (R-Texas) |
| JEFFERY C. MORTIER New | Prof Staff on E&C Cmte and LA Rep Whitfield |
| JOSEPH V VASAPOLI New | Min.Counsel, Energy&Comm, Special Asst. DOE |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.